In Brief Rothbart et al. use a recently developed histone peptide microarray platform to analyze the specificities of over 100 commercially available and widely used antibodies against histone posttranslational modifications. A publicly available database that is interactive and is designed to expand through user participation has been created, http://www.histoneantibodies. com.
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INTRODUCTION
Histones and their numerous posttranslational modifications (PTMs) are fundamental to the process of cell fate decision making and organismal development. Consistent with this, studies have shown that both histone mutation and PTM misregulation contribute to the initiation and progression of a wide number of human diseases, including cancer and neurological disorders (Bannister and Kouzarides, 2011; Dawson and Kouzarides, 2012; Funato et al., 2014; Jakovcevski and Akbarian, 2012; Lewis et al., 2013; Rothbart and Strahl, 2014) . Histone modifications function in part as docking sites for effector proteins harboring specialized, evolutionarily conserved domains that ''read'' the single or combinatorial modification states of histones (Gardner et al., 2011; Jenuwein and Allis, 2001; Strahl and Allis, 2000) .
The mass production and distribution of PTM-specific histone antibodies (more than 1,000 are commercially available to date) have greatly facilitated the study of these histone marks and their impact on chromatin function (Perez-Burgos et al., 2004; Turner and Fellows, 1989) . Histone PTM antibodies are essential for numerous applications in chromatin research, including immunoblotting, immunostaining, and chromatin immunoprecipitation (ChIP). Indeed, large-scale epigenomics ''road map'' efforts like the Encyclopedia of DNA Elements (ENCODE) projects depend on these antibodies for genome-wide mapping of histone PTM distribution Gerstein et al., 2010; Kharchenko et al., 2011) . However, recent studies have made some surprising and alarming observations regarding the behavior of histone PTM antibodies, including off-target recognition, strong influence by neighboring PTMs, and an inability to distinguish the modification state on a particular residue (e.g., mono-, di-, or tri-methyl lysine) (Bock et al., 2011; Egelhofer et al., 2011; Hattori et al., 2013; Nishikori et al., 2012; Rothbart et al., 2012c) . Consequently, poor antibody choice can lead to misinformed conclusions regarding the location and function of the histone PTM being queried (Baker, 2015) . Because our understanding of how histone PTMs contribute to normal biology and human disease depends on the quality of the antibodies being used, continued rigorous quality control is needed for accurate data interpretation and continued progress in the field.
Herein, we describe an interactive web resource, The Histone Antibody Specificity Database, for histone PTM antibody characterization built on our recently developed high-density histone peptide microarray platform Rothbart et al., 2012b) . This open-access database, which at the time of publication provides characterization data on over 100 of the most frequently used and cited commercially available histone PTM antibodies, serves as an interactive, sustained, and evolving platform for the interrogation of antibody specificity that will greatly aid epigenetics researchers in making more informed histone antibody choices. We provide several vignettes of common antibody behavior drawn from this resource, including off-target recognition and sensitivity to neighboring PTMs, and we highlight how these behaviors could influence the conclusions made from their use in various applications. biotinylated histone peptides harboring PTMs (lysine acetylation, lysine/arginine methylation, and serine/threonine phosphorylation) alone and in relevant combinations that are largely derived from mass-spectrometry-based proteomics datasets (Table S1 ) (Pesavento et al., 2008; Sidoli et al., 2012; Young et al., 2009 Young et al., , 2010 . This platform allows for robust and comprehensive characterization of the behavior of histone-interacting proteins, including the specificity of histone antibodies ( Figure 1A ) (Cai et al., 2013; Rothbart et al., 2012a Rothbart et al., , 2012c Rothbart et al., , 2013 . Notably, antibody reactivity with differing modification states (e.g., mono-, di-and tri-methyl lysine) and the influence of epitope recognition by neighboring histone PTMs can be determined with high precision. With this platform, we analyzed over 100 histone PTM antibodies that are commercially available from nine suppliers who market these products to specifically recognize various methylated, acetylated, and (Table S2 ) are marketed to recognize. Lysine acetylation (ac); lysine methylation (me1/me2/me3*); arginine methylation (me1/me2a/me2s**); and serine and threonine phosphorylation (P). *Histone lysine methylation occurs in three forms (mono-, di-, and trimethylation). **Arginine methylation also occurs in three forms (monomethylation, symmetric, and asymmetric dimethylation).
(C) Screenshot of the home page for http://www.histoneantibodies.com, an interactive Java-based web resource displaying histone antibody specificity data from peptide microarray experiments. Users can query data by entering strings in the search bar and by clicking on their histone and posttranslational modification of interest.
phosphorylated residues (and their combinations) on the core and variant histones, yielding over 25,000 specific binding measurements ( Figure 1B and Table S2 ).
To create a versatile platform that is easily accessible to the broad scientific community for interrogation of histone antibody specificity data, we built an interactive web platform, http:// www.histoneantibodies.com ( Figure 1C) , which utilizes the D3js JavaScript library. Users can query the database by search bar ( Figure 1C, top) or by histone and sequence context (Figure 1C , bottom) for antibody data specified by PTM of interest, histone, residue, company, or product number (Table S2 ). All datasets for a particular PTM of interest are presented together to allow users to make direct comparisons. Data are presented on the website as interactive heat maps (Figures S1A and S1B) and bar graphs ( Figure S1B ). Hovering over individual data points in these graphs gives the user information on corresponding peptide length, PTMs, and sequence context (Table S1 ). For heat maps, array signal intensities are ordered from strongest (yellow) to weakest (blue) relative to a reference target (black)-the peptide harboring the PTM(s) on the antibody product label. All peptides containing the reference target are outlined in red.
For bar graphs, array results are presented as normalized mean intensities ± SEM on a scale from 0 (undetectable binding) to 1 (strong binding). The target peptide is depicted as a green bar. Orange bars indicate target-containing peptides that display enhanced signal compared to the reference. These are PTM combinations that enhance antibody binding. Light blue bars indicate target-containing peptides that display a diminished signal compared to the reference. These are PTM combinations that inhibit antibody binding. Gray bars indicate off-target peptides. Analysis of all tested histone PTM antibodies allowed us to bin unfavorable behavior into three general categories: (1) an inability to distinguish states of methylated lysine, (2) sensitivity to neighboring PTMs, and (3) recognition of off-target modifications. Examples of these types of behavior are discussed below.
Distinguishing States of Methylated Lysine
Of the 38 di-and tri-methyl lsyine antibodies screened, 16 cross-reacted with lower states of lysine methylation on a target residue, and 1 recognized a higher state of lysine methylation. Notably, this does not appear to be a general property of methyl lysine antibodies to a particular target residue. For example, analysis of five H3K4me3 antibodies shows that several cross-react with H3K4me2 peptides, while others are selective for the H3K4me3 mark (Figure 2A, left) . This is also true for H3K4me2 antibodies, some of which cross-react with H3K4me1 peptides (Figure 2A, right) . Importantly, the three states of methylation at H3K4 have reportedly differential regulatory functions (Barski et al., 2007) , yet analysis of the genomic distribution of these marks by ChIP-seq in HEPG2 cells, using antibodies that cross-react with lower-order methylation states by microarray, shows overlapping signal for H3K4me3 and H3K4me2 across transcription start sites and gene bodies ( Figure S2A ) and for H3K4me2 and H3K4me1 across enhancer elements ( Figure S2B ). Collectively, these results highlight the importance of antibody choice for accurately discerning between various states of lysine methylation and suggest antibody cross-reactivity may contribute to inaccurate mapping of histone lysine methylation states in genome-wide analyses due to antibody cross-reactivity.
Sensitivity to Neighboring PTMs
Neighboring PTMs can impact not only the ability of a reader domain to bind its target modification but also the ability of histone PTM antibodies to recognize their target epitopes (Bock et al., 2011; . As an example, H3K9me3 antibodies show varying degrees of sensitivity-both enhanced and perturbed epitope recognition-to neighboring PTMs that surround H3K9 ( Figure S2C ). Most notably, H3K9me3 antibodies we screened show differential tolerance to neighboring H3S10 phosphorylation ( Figure 2B , left)-a mitotic combinatorial ''methyl/phospho switch'' known to eject proteins like heterochromatin protein 1 (HP1), for example, from mitotic chromatin (Fischle et al., 2005; Hirota et al., 2005) . Neighboring H3K9me3 also impacts epitope recognition by H3S10p antibodies (Figure 2B, middle) . The H3K9me3 and H3S10p antibodies insensitive to this methyl/phospho switch cannot distinguish between dually marked H3 tails and isolated H3K9me3 or H3S10p marks. However, several antibodies developed to recognize this methyl/phospho PTM combination are capable of this distinction by microarray analysis ( Figure 2B , right). Collectively, these findings suggest that H3K9me3 and H3S10p antibodies sensitive to neighboring phosphorylated and methylated residues, respectively, under-represent these singly marked histone H3 populations in mitosis and that combinations of all three selective reagents may be required to accurately detect and map this dually marked chromatin signature.
Consistent with our previous observations (Rothbart et al., 2012c) , microarray analysis shows that site-specific H4 acetyl antibodies preferentially bind epitopes with iterative increases in acetylation content ( Figure 2C ). For example, all of the H4K5ac antibodies screened show enhanced signal on peptides containing H4K5ac and one or more H4Kac sites, with iterative increases in acetylation content (up to 4 sites on a single peptide) being preferred epitopes for the majority of H4 acetyl antibodies screened. Importantly, this does not appear to be due to charge masking, as an H4K12ac peptide with all other lysines mutated to glutamine (K5, K8, K16, and K20) is only recognized by H4K12ac antibodies and by a tetra-acetyl H4 antibody (4ac) that also recognizes H4K12ac peptides in isolation ( Figure 2C ).
Off-Target PTM Recognition
A significant number of histone PTM antibodies that were screened demonstrated cross-reactivity with unintended modifications. For example, while H3K9me3 Ab2 is insensitive to neighboring H3S10p ( Figure 2B , left) and does not recognize lower-order methylation states of H3K9 ( Figure 2D ), this antibody suffers from off-target recognition of other tri-methylated lysine residues, including H3K27me3, H3K23me3, and H3K18me3 ( Figures 2D and S3 ). While the latter two PTMs are found in lower abundance in cells (Lin et al., 2014 ) and may therefore not be problematic under physiologic conditions, cross-reactivity with H3K27me3 may be problematic for this antibody, enriching for signals present in regions of facultative heterochromatin where H3K9me3 may or may not reside.
H3K9 and H3K27 are both found in an ARKS motif, and, indeed, we and others have shown that the H3K9 methyltransferase G9a can modify H3K27 in vitro ( (Tachibana et al., 2001 , and data not shown). While this may serve as an explanation for antibody mis-targeting between these sites, we note that this issue of off-target methyl lysine reactivity does not appear to be restricted to residues found in similar sequence contexts. Indeed, analysis of H3K27me3 antibodies shows that several preferentially bind H3K4me3 peptides ( Figure 3A ). This off-target recognition is strongly enhanced when H3K4me3 is presented in combination with neighboring acetylation marks, a native context of H3K4me3 found in cells (Taverna et al., 2007 antibody on whole-cell extracts from the budding yeast Saccharomyces cerevisiae, an organism whose chromatin lacks H3K27 methylation (Garcia et al., 2007) . To our surprise, a 17-kDa band corresponding to signal from histone H3 was detected with H3K27me3 Ab3 (Figure 3B, left) . Furthermore, this 17-kDa band was undetectable following deletion of SET1, the sole H3K4 methyltransferase in budding yeast (Figure 3B , right) (Briggs et al., 2002) , demonstrating cellular cross-reactivity of this H3K27me3 antibody with H3K4me3-marked histones in cells and presenting a potential conundrum for bivalency readouts (Bernstein et al., 2006) featuring these antibodies.
Another type of antibody cross-reactivity we observed was epitope recognition in the absence of a target PTM. This can be seen with several analyzed H3S10p antibodies that recognize H3 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) peptides combinatorially modified in various ways in the presence ( Figure 3C , top) or absence ( Figure 3C , bottom) of this phosphorylation mark. H3S10p is a dynamic histone PTM found in low abundance at transcriptionally active genes in interphase cells (Davie, 2003) and is highly enriched in mitotic chromatin during condensation (Wei et al., 1999) . To confirm the behavior observed with H3S10p antibodies, we tracked the cell cycle dynamics of this PTM using an H3S10p antibody the arrays would classify as specific for this mark (Ab1) and one the arrays would classify as a pan N-terminal H3 antibody (Ab2). HeLa cells were arrested at G1/S by double thymidine block, and extracts were immunoblotted at time points following release to track H3S10p through mitosis ( Figure 3D ). Consistent with previous observations (Davie, 2003; Wei et al., 1999) , H3S10p Ab1 signal was weak through S phase and was pronounced in mitotic extracts ( Figure 3D ). In contrast, H3S10p Ab2 signal was equal in all cell-cycle fractions, consistent with characterization by array of this antibody's behavior as an N-terminal-specific, pan H3 antibody. 
ChIP Validation of Antibody Behavior
A gold standard for histone PTM antibodies is their utility in ChIP assays. We therefore questioned whether characterization of antibodies by peptide microarray could inform target recognition in ChIP. We chose two H3K27me3 antibodies that displayed acceptable behavior by peptide microarray to test in ChIP-seq. Analysis of wild-type mouse embryonic stem cells (ESCs) showed a strong correlation of read distribution between the two antibodies ( Figures 4A, 4B , and S4A). To assess the specificity of these antibodies for H3K27 methylation, parallel ChIPseq experiments were performed in ESCs lacking H3K27 methylation due to genetic deletion of the Eed core subunit of the Polycomb Repressive Complex 2 (PRC2) histone methyltransferase complex) ( Figures 4A, 4B , S4B, and S4C) (Chamberlain et al., 2008 . Meta-analysis of the average signal for each antibody over all H3K27 peaks in the genome (n = $8,500) shows that these antibodies are specific and that signal is lost in the knockout line ( Figure 4B ).
While ChIP experiments comparing wild-type and histone methyltransferase null cell lines inform on antibody specificity, they can provide only correlative information on epitope recognition. We therefore sought to define more directly the specificity of histone PTM antibodies for endogenous nucleosomal epitopes by performing immunoprecipitations (IPs) of mouse ESCs (E14) spiked with a library of semi-synthetic DNAbarcoded mononucleosomes (Internal Standard Calibrated ChIP; IceChIP) uniformly modified by H3K4me3, H3K9me3, H3K27me3, H3K36me3, and H3K79me2 (Grzybowski et al., 2015) . We tested two H3K27me3 antibodies and two H3K79me2 antibodies using both native and cross-linking IP conditions ( Figures 4C and 4D) . The series of semi-synthetic nucleosomes marked with H3K27me3 were significantly enriched with both H3K27me3 antibodies under both native IP and cross-linking conditions. In contrast, H3K79me2 Ab1, but not Ab2, modestly enriched for semi-synthetic nucleosomes marked with this PTM under native conditions, and neither antibody enriched for H3K79me2 nucleosomes under cross-linking conditions. Collectively, these data highlight the utility of semisynthetic nucleosomes for histone PTM antibody characterization within ChIP experiments and suggest that the choice to cross-link chromatin in a ChIP can have consequences on the resultant IP.
DISCUSSION
Antibody choice is the single most important element of many epigenetic experiments; yet there are many widely used commercial preparations available for a given mark, and they do not all perform equivalently. In this report, we unveil a database that documents the behavior of over 100 histone PTM-specific antibodies on peptide microarrays. This portal provides an interactive search tool, allowing investigators to access and compare antibodies based on histone type, PTM type, vendor source, and other criteria. Importantly, the database is built to evolve and grow over time as additional antibodies are characterized. To facilitate community involvement, inclusion of new antibody data can be achieved through investigator-supplied or vendorsupplied microarray results using the Upload Data tab in the main page portal. A simple user guide walks investigators through the few steps required to integrate array results on the webpage. Briefly, after an array is scanned, a three-column comma-separated value (CSV) file is uploaded that contains a pixel index or spot ID number, green signal intensity, and red signal intensity. A sample formatted data file is available for viewing and downloading on the site. The database and web portal are built automatically via Bash script, allowing newly acquired results to be rapidly analyzed and added to the site with minimal effort through a curator. As the need for precise characterization of an antibody's target epitope grows, the use of the array platform utilized in this report, which is commercially available through multiple vendors including EpiCypher and Millipore, will make this possible. Significantly, this database will organically grow with minimal support needed and, further, can adapt to changing array platforms. Using the information obtained from the Histone Antibody Specificity Database, we highlight several vignettes describing the type of antibody behaviors that are seen with antibodies raised against methyl lysine, acetyl lysine, and phosphoserine on histone residues. Antibodies examined displayed a variety of results, ranging from very specific target recognition to difficulties in recognizing a precise methyl state, acetyl site location, and the specific target site itself. The antibodies exhibiting these issues could have severe consequences in data interpretation, which may depend on the abundance of the on-target mark relative to the off-target PTM. Antibody misbehavior may also be application specific (e.g., immunoblotting versus ChIP). Our array findings revealed the capacity of some of these antibodies to show the same behavior in various applications, for example, western bot ( Figure 3A) and ChIP (Figure 4) . Thus, the results available in the database offer an important view of each antibody and what the total possibilities are.
While another available database of antibody specificity is available (Egelhofer et al., 2011) , this Antibody Validation Database (AVD) specifically offers the demonstration of an antibody's ability to work or not in western blot or ChIP (e.g., seeing a band in extracts or sequencing reads) but does not report on the actual specificities of each antibody for all possible target possibilities. We argue that knowing the PTM ''interactome'' represents the fundamental foundation that investigators need to start with when choosing an antibody for their studies. Thus, the Histone Antibody Specificity Database is meant to complement the AVD, but not replace it. To connect these two databases, we have created hyperlinks to query available AVD data for a PTM of interest. These links are accessible by mousing over the antibody name on the heat maps ( Figure S1B ). In addition, users can also query available ENCODE data and lot information and link directly to the product page for a given antibody from the same window.
It is important to highlight that results from the Histone Antibody Specificity Database may not translate to actual results in other applications. As mentioned above, while an antibody may show ability to bind with an off-target PTM, it may not be an issue if that off-target PTM is not present in a particular cell type or is far less abundant in bulk histones (Lin et al., 2014) . Therefore, careful integration of our microarray data with available mass-spectrometry-based proteomics analysis of histone PTMs will allow investigators to predict whether off-target antibody behavior may be problematic in their specific application. However, there are likely cases where off-target recognition or failure to recognize the appropriate methyl or acetyl state can skew results, as shown in Figures 2D, 3C , 3D, 4C, and 4D. Histone core modifications like H3K79 methylation exemplify this concept. Our analysis of H3K79 methyl antibodies shows specificity on peptide arrays (as might be expected given the antibodies are raised against peptide antigens) but failure in applications where the modification must be recognized in its physiologic state. Since the peptide epitope does not represent the nucleosomal context of the mark, these antibodies fail to recognize the PTM in non-denaturing conditions (they work in denaturing assays like immunoblotting). Thus, as a first pass of selecting the right reagent, array analysis provides a highthroughput measure of the scope of on/off-target binding. But as the arrays are dense surfaces of peptide epitopes, and the antibody is dilute and mono-dispersed, which is an excellent surrogate for immunoblotting and for exposed epitopes, the arrays may not represent assays like ChIP in that the format is reversed (dense surface of antibody, sparse epitope), and the nucleosomes must remain largely intact and folded.
The Histone Antibody Specificity Database represents an invaluable resource and tool for the scientific community that relies on histone PTM antibodies as detection reagents in chromatin and epigenetics research. Collectively, the data from this web portal will now greatly aid in informing investigators about specificity of antibodies they have previously used, and the website will enable better decision making for which reagent to use in future experiments among the myriad of commercially available antibodies. It is our hope that making this specificity data publicly available will facilitate more informed antibody choices, aiding in the interpretation of results obtained with these critical reagents.
EXPERIMENTAL PROCEDURES Materials
Biotinylated histone peptides (Table S1 ) were synthesized by Fmoc chemistry, purified by reverse phase high-pressure liquid chromatography (HPLC), and analyzed by MALDI-TOF mass spectrometry (MS) and analytical reverse phase HPLC as previously described (Rothbart et al., 2012b) . A list of antibodies screened in this study can be found in Table S2 .
Histone Peptide Microarrays
Array fabrication, antibody detection, and data analysis were performed as described (Rothbart et al., 2012b) with the following modifications. Each peptide listed in Table S1 was spotted in triplicate eight times per array. Triplicate spots were averaged and treated as a single value for subsequent statistical analysis. Heat maps were generated with Java TreeView (Saldanha, 2004) .
Cell Culture, Manipulation, and Protein Harvest HeLa cells (ATCC) were cultured in MEM (Life Technologies) supplemented with 10% fetal bovine serum (FBS), maintained in a 37 C incubator with 5% CO 2 and passaged every 2-3 days. Eed À/À (referred to as KO) ESCs (gift from Weipeng Mu and Della Yee) were generated from Eed fl/fl (referred to as WT) mouse ESCs transfected with a CAG-cre-ERT2 transgene and treated with tamoxifen. Cells were cultured as previously described (Chamberlain et al., 2008) . For double-thymidine block, HeLa cells were synchronized by treatment with 2 mM thymidine (Sigma) for 16 hr, followed by release for 8 hr and re-treatment with 2 mM thymidine for 16 hr. HeLa cells were lysed in cold buffer containing 10 mM PIPES (pH 7.0), 300 mM sucrose, 100 mM NaCl, 3 mM MgCl 2 , 13 EDTA-free protease inhibitor (Roche), 13 phosphatase inhibitor cocktail (Sigma), 0.1% Triton X-100, and endonuclease (Pierce) before being resolved by SDS PAGE. Whole cell protein extracts from wildtype (BY4741) and set1D Saccharomyces cerevisiae were prepared using SUMEB buffer containing 10 mM MOPS (pH 6.8), 1% SDS, 8 M urea, 10 mM EDTA, and 0.01% bromophenol blue. Briefly, 500 ml of buffer and the equivalent volume of glass beads were added to approximately 36 optical density (OD) equivalent of cells. Extracts were prepared by beating the beads for 6 min followed by centrifugation. Cleared extracts were serially diluted 2-fold using SUMEB buffer and boiled for 10 min at 95 C prior to SDS PAGE and immunoblotting with the indicated antibodies.
ChIP
Wild-type and Eed À/À ESCs were harvested and fixed for 10 min at room temperature in 1% formaldehyde in phosphate-buffered saline (PBS) and then quenched by adding glycine to 0.125 M for 5 min at room temperature. 50 ml Protein A and Protein G Dynabeads (Life Technologies) were prepared by incubating with 5 mg H3K27me3 (Abcam ab6002) or 5 mg H3K27me3 (Millipore 07-449) overnight. Cells were sonicated for 10 cycles of 30 s on 1 min off using a Bioruptor (Diagenode) to an average size of 200 to 600 bp and incubated overnight with antibody bead complexes. The beads were washed eight times in RIPA buffer (10 mM Tris-HCl [ph 8.0], 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine) and eluted in 100 ml of 1% SDS, 100 mM NaHCO 3 for 15 min at 65 C.
Following crosslink reversal, samples were treated with RNaseA and Proteinase K before purification using a Clean and Concentrator ChIP kit (Zymo Research).
Library Preparation
Libraries were prepared using standard methods for Illumina sequencing using NEB Next ChIP kits (New England Biolabs), and samples were submitted to the UNC High-Throughput Sequencing Facility for sequencing on an Illumina HiSeq2000.
Bioinformatics Analysis
Reads were aligned to the mouse genome (mm10) with bowtie2 using the -sensitive parameter (Langmead and Salzberg, 2012) , and enriched regions were identified using macs2 v2.1.0 (Zhang et al., 2008) using the broadpeak setting. Genome browser tracks were created using the HTSeq python library (Anders et al., 2015) and are available for use as a UCSC Genome Browser track hub (GEO: GSE66902) at http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?token=cvmbiscshnclfud&acc=GSE66902. Comparisons of WT and KO cell lines for each antibody were carried out using R (R Core Team, 2014).
Bar-Coded Designer Nucleosomes Construction
Bar-coded semi-synthetic nucleosomes were made as previously described (Grzybowski et al., 2015) . Posttranslational modifications of histone H3 included H3K4me3, H3K9me3, H3K27me3, H3K36me3, H3K79me2, and unmodified histone H3 (WT).
ICeChIP
Native ICeChIP was performed with chromatin isolated from mouse ES cells (E14) as previously described (Brand et al., 2008) . Aforementioned chromatin was doped with semi-synthetic nucleosomes bearing symmetrical H3K4me3, H3K9me3, H3K27me3, H3K36me3, H3K79me2, as well as non-modified H3; each mark was identifiable by a unique DNA sequence. For crosslinked ICeChIP, the same source and amount of digested and HAP purified chromatin was subjected to a 15-min treatment with 0.1% freshly cracked formaldehyde at room temperature. Crosslinking was extinguished with one volume of 23 X-link ChIP buffer 1 (66 mM Tris [pH 7.5], 300 mM NaCl, 10 mM EDTA, 2% NP-40, and 0.5% N-lauroylsarcosine). The concentration of chromatin was adjusted to 20 mg/ml with appropriate ChIP buffer supplemented with 50 mg/ml BSA (NEB). Elutions were supplemented with NaCl up to 200 mM, EDTA up to 10 mM, and 20 mg of proteinase K (Roche) and incubated for 2 hr at 55 C. To purify DNA, three volumes of SPRI beads (18% PEG8000, 1 M NaCl, and 1 mg/ml Sera-Mag SpeedBeads carboxylate-modified magnetic particles) were added to the elution and pipetted ten times up and down followed by 5 min incubation at room temperature. Magnetic beads were collected on the side of the tube with a magnet, and two 30-s washes with 200 ml of 80% ethanol (EtOH) on the magnet were performed. Tubes were then taken out of magnetic rack, and 50 ml of TE buffer was added to beads and mixed by pipetting up and down. Enrichment of each histone PTM was evaluated by qPCR using TaqMan chemistry. Enrichment was calculated using the DDCt method.
Enrichment = 2 ðCtinputÀCtIPÀlog2ðdfÞÞ ;
where df is a dilution factor between IP and input. Subsequently, enrichment for each PTM was normalized to the enrichment of the on-target nucleosome (e.g., for H3K27me3 antibody, on-target would be H3K27me3 semi-synthetic nucleosome). Experiments were performed in technical triplicate. Errors were estimated using partial derivation. All ICeChIP data have been deposited under GEO: GSE60378.
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